SCHEMBL4489171

SCHEMBL4489171

COc1cccc(CNS(=O)(=O)c2cccc3c(O)cccc23)c1OC

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA14 Q9ULX7 1/20 0.49
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
ATM Q13315 1/20 0.46
FABP4 P15090 2/20 0.45
NSD2 O96028 2/20 0.45
HIF1A Q16665 1/20 0.45
ALDH1A1 P00352 2/20 0.44
MAPK1 P28482 1/20 0.44
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4480649 0.90 MEN1 (0.53) LMNANPSR1KMT2AMEN1FABP4
SCHEMBL4446873 0.86 NSD2 (0.62) LMNANPSR1SMN1; SMN2CA12CA1
Hydrochloric Acid SCHEMBL4448811 0.85 NSD2 (0.63) LMNANPSR1SMN1; SMN2CA12CA1
SCHEMBL4449293 0.83 MEN1 (0.45) LMNANPSR1SMN1; SMN2CA12CA1
SCHEMBL4471169 0.80 LMNA (0.50) LMNANPSR1SMN1; SMN2CA12CA1
SCHEMBL4493208 0.79 MEN1 (0.49) LMNANPSR1SMN1; SMN2CA12CA1
SCHEMBL4492415 0.79 ALDH1A1 (0.55) CA12CA1CA2KMT2AMEN1
SCHEMBL4482015 0.78 MEN1 (0.47) LMNANPSR1SMN1; SMN2KMT2AMEN1
SCHEMBL4478609 0.77 CA12 (0.46) LMNANPSR1SMN1; SMN2CA12CA1
SCHEMBL4487513 0.77 CA2 (0.60) CA12CA2NSD2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US claimed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US claimed
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US disclosed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215645-A1 Amide derivatives OGG1, HDAC1, BCL2A1 LMNA 941/4885NPSR1 3072/4885SMN1; SMN2 2959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.